Chidamide Plus R-CHOP in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma With Other Molecular Subtypes

Prior treatment

• Patients who meet any of the following criteria will be excluded from the study：
  • Currently enrolled in another clinical trial；
  • Received prior lymphoma treatment with alternative regimens before enrollment;
  • Presence of concurrent malignant tumors;
  • Deemed ineligible for participation by the investigator's judgment；
  • Presence of severe psychiatric or neurological disorders that may impair the ability to provide informed consent and/or affect the reporting or observation of adverse events；
  • Patients unable to comply with follow-up requirements；
  • Pregnant or lactating women, and patients of childbearing potential unwilling to use contraception;
  • Active infection or uncontrolled HBV (HBsAg positive and/or HBcAb positive and HBV DNA positive), HCV positive

• Patients must meet all of the following inclusion criteria to be eligible for enrollment:
  • ≥18 years of age;
  • Diffuse large B-cell lymphoma diagnosed by pathological diagnosis according to WHO 2016 classification criteria;
  • Molecular subtyping, determined through high-throughput sequencing of pathological tissue or peripheral blood, is categorized as the "Other" subtype;
  • Immunohistochemistry revealed overexpression of MYC and BCL2: MYC ≥ 40%, BCL2 ≥ 50%;
  • Measurable lesions identified on cross-sectional imaging through diagnostic modalities (computed tomography \[CT\] or magnetic resonance imaging \[MRI\]) are defined as the presence of at least one two-dimensional lesion with a maximum cross-sectional diameter (GTD) ≥1.5 cm, irrespective of the short-axis diameter;
  • The Eastern Cooperative Oncology Group (ECOG) performance status score is ≤2；
  • Adequate hepatic function is defined as: total bilirubin (TBIL) ≤ 3 times the upper limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤5 × ULN; alkaline phosphatase (ALP) ≤ 5 × ULN; serum creatinine ≤ 1.5 × ULN or creatinine clearance ≥ 35 mL/min as calculated by the Cockcroft-Gault formula;
  • Voluntary participation with willingness to provide the aforementioned treatment data, accompanied by a signed and dated informed consent form.